Member Info for WeTookPelham

Share prophets Nigel Somerville...

Lol.

Nothing more to say than that.

"So Seth thinks he can get £6m ish per mab on a non exclusive basis. Someone will have to go much higher for exclusivity but beware the tail which comes alongside. Many firms may notwant to play for the other assets if x is attached."

How much higher are we thinking for exclusivity? Educated guesses?

Strong finish and unusual for sclp following a presentation, no matter how good it is! Perhaps things are changing!?

P.s. Good posts today c11, but that was a bit of a unnecessary dig in your last post IMO.

An observation from the comments only as wasn't able to watch, but seemed to me like this presentation was, for the first time perhaps (?), focused more on the potential for deals/negotiations rather than the science?

If so, I'm super pleased and excited. It shows the progress and where Scancell are (finally) at now.

Another question, would the five competing parties have been aware that they were in competition with other parties until today? Was LD trying to cause some panic between them I wonder?

Yes, a running commentary would be useful please :)

Https://www.proactiveinvestors.co.uk/companies/news/1039647/scancell-geared-up-for-busy-2024-1039647.html#

https://www.proactiveinvestors.co.uk/companies/news/1039647/scancell-geared-up-for-busy-2024-1039647.html#

"30/1/2024

07:29 sci102: RNS out but no additional update on SCOPE. They should have data on at least 4-5 additional patients and hopefully they'll say more at the presentation."

Do we think there could be another intra day RNS? They seem to like those now.

"This represents a potential $1.5 billion per annum market and we anticipate significant interest from potential partners"

This is the kind of thing I want to see in an RNS. Stating the obvious perhaps but still important to say it IMO. A big clue you could say.

The more pertinent question is who is waiting in the wings.

Yes, good point Bobbust, I was just about to say the same after checking myself. Seems like the data on LSE isn't the most accurate.

Flutter not flatter*!

Thanks for highlighting bobbust, I would not have noticed that this is the first time with the half year results that there has been presentation with a q&a after.

It is interesting/intriguing. And yes perhaps "worth a flatter" indeed! But that spread isn't helping perhaps? "still" 10%, which I think is unusual in it's own right?

Https://www.spectator.co.uk/article/where-are-the-smart-investments-under-a-starmer-government/

"Where are the smart investments under a Starmer government?

3 hours ago — ... Scancell in immunology; Destiny Pharma in infection prevention; and Angle in liquid biopsy technology. Shield Therapeutics, with an iron deficiency drug."

Can't see the full article unfortunately, but get the gist. P.s. Not to start a heated debate re politics/election.

We agree to disagree on the point of the RNS titles, which is fair enough, it's the whole point of forum like this I guess.

But my point is the private investors, in particular those interested in the bio, may have had a closer look at the RNS(s) with more descriptive titles, and perhaps even smaller fund manager types, share tipsters etc. Who knows. Lots of other companies release RNS's with far more descriptive titles.

But the more interest the better IMO for the interim at least, whilst we wait for the those who will make the biggest difference i.e. big pharma.

...Plus "Exceptional results" - quite eye opening and fantastic to to see this written. Again that should have been in the RNS title and/or subtitle.

Some other observations, typical of Scancell to release another fantastic RNS on an overall terrible day for the broader market!

Also, why didn't they use the subtitle of the RNs as the actual title i.e. "MHRA approval to add a third cohort using iSCIB1+ to the SCOPE trial"

IMO having MRHA approval would certainly have piqued more interest.

Also I hadn't topped up for a while, yesterdays RNS has (re) cemented why most of us are here, so figured time for a small top up.

Thanks miavoce, I stand corrected. That article does highlight some interesting points though still regarding the approach a bio like Scancell has to take. Definitely worth a read.

C7 wrote yesterday "I wonder why we did the most recent raise when we did, knowing the results coming shortly were going to be exceptional?"

That article goes somewhat towards explaining it, to me at least. Scancell have to cover for all eventualities, and I guess it makes them less susceptible to a cheap buyout?

Https://www.fiercebiotech.com/biotech/biotech-dealmakers-its-everything-everywhere-all-once

Whilst EE's explanation regarding the timing i.e. intra day release makes the most sense, the happy clappy in me is curious, much like cleanerworld.

Yes the MHRA signed off, but the RNS is clearly well prepared and pre prepared. Was it really time critical? i.e. I think they would normally do a 7am for this kind of news?

P.s. good to see you posting c7.

Unavailable to trade online on my broker ATM. 🤔 Interesting.